Published in

SAGE Publications, Therapeutic Advances in Neurological Disorders, 5(5), p. 255-266, 2012

DOI: 10.1177/1756285612453972

Links

Tools

Export citation

Search in Google Scholar

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

Journal article published in 2012 by Verena Isabell Leussink, Leila Husseini, Clemens Warnke ORCID, Erasmia Broussalis, Hans-Peter Hartung, Bernd C. Kieseier
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.